immuno-oncology

News

NICE clears NHS use of Roche's Tecentriq in bladder cancer

NICE has recommended routine NHS access to Roche's cancer immunotherapy Tecentriq for some bladder cancer patients, four years after it was first made available via the Cancer Drugs Fund (C

News

Keytruda's liver cancer approval secured by new study

Merck & Co's FDA approval for Keytruda in advanced liver cancer looks secure, after an Asian clinical trial found that the cancer immunotherapy improved survival in these patients.

News

Boehringer Ingelheim, Biberach, Germany, February 2007

Boehringer buys Abexxa, bolstering its immuno-oncology pipel...

Boehringer Ingelheim has agreed to buy US biotech Abexxa Biologics, its second acquisition in the cancer immunotherapy area in the space of a year.

News

ESMO21: Libtayo extends survival in first-line NSCLC, challe...

There's no shortage of cancer immunotherapies trying to knock Merck & Co's Keytruda off the top of the tree in previously-untreated non-small cell lung cancer (NSCLC).

News

Keytruda backed by NICE for late-stage oesophageal cancer

MSD's Keytruda has become the first immunotherapy cleared by NICE for previously-untreated patients with advanced oesophageal cancer, making it an option for routine NHS treatment.

News